Comparative Pharmacology
Head-to-head clinical analysis: HYDRO SERP 50 versus TRIBENZOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDRO SERP 50 versus TRIBENZOR.
HYDRO-SERP "50" vs TRIBENZOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrochlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water. Reserpine depletes catecholamines (norepinephrine, dopamine) from peripheral sympathetic nerve endings, reducing vascular tone and heart rate.
TRIBENZOR is a fixed-dose combination of olmesartan, an angiotensin II receptor blocker that inhibits the vasopressor and aldosterone-secreting effects of angiotensin II, and amlodipine, a dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cells, resulting in vasodilation.
Hydrochlorothiazide 50 mg orally once daily.
Tribenzor (olmesartan medoxomil/amlodipine/hydrochlorothiazide) is available in fixed-dose combinations. Typical adult dose: one tablet orally once daily. Starting dose depends on prior antihypertensive therapy; maximum recommended dose is olmesartan 40 mg/amlodipine 10 mg/HCTZ 25 mg per day.
None Documented
None Documented
50-100 hours (prolonged in renal impairment; half-life up to 200 hours in severe renal disease)
Terminal half-life 9-11 hours; supports once-daily dosing
Renal (50-70% as unchanged drug and metabolites), biliary/fecal (20-30%)
Renal: 50-60% as unchanged drug and metabolites; Biliary/Fecal: 40-50%
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination